Trials / Completed
CompletedNCT02634320
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate or Risperidone Long Acting Injection
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole Lauroxil | Monthly IM injection |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2017-07-11
- Completion
- 2017-07-11
- First posted
- 2015-12-18
- Last updated
- 2018-12-04
- Results posted
- 2018-11-08
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02634320. Inclusion in this directory is not an endorsement.